Patents by Inventor Tianli Zheng

Tianli Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9068169
    Abstract: The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stems cells having a high propensity to differentiate into insulin producing cells or into insulin producing cell aggregates.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: June 30, 2015
    Assignee: RENEURON, INC.
    Inventors: Wen-Ghih Tsang, Tianli Zheng, Wei Liu
  • Publication number: 20090246178
    Abstract: The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stems cells having a high propensity to differentiate into insulin producing cells or into insulin producing cell aggregates.
    Type: Application
    Filed: May 2, 2008
    Publication date: October 1, 2009
    Applicant: RENEURON, INC.
    Inventors: WEN-GHIH TSANG, TIANLI ZHENG, WEI LIU
  • Patent number: 7371576
    Abstract: The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stems cells having a high propensity to differentiate into insulin producing cells or into insulin producing cell aggregates.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: May 13, 2008
    Assignee: Reneuron, Inc.
    Inventors: Wen-Ghih Tsang, Tianli Zheng, Wei Liu
  • Patent number: 7101546
    Abstract: This invention relates to the discovery that an intermediate, differentiated stage of pancreatic stem cells exist that can be matured in situ into a stable cell line that produces insulin in response to glucose. These cells are advantageous in that they are both expandable and stable in culture. This invention avoids the step of culturing the intermediate stage stem cells into later stage pancreatic cells.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: September 5, 2006
    Assignee: AmCyte, Inc.
    Inventors: Wen-Ghih Tsang, Tianli Zheng, Yanping Wang
  • Publication number: 20040141957
    Abstract: This invention relates to the discovery that an intermediate, differentiated stage of pancreatic stem cells exist that can be propagated in a stable manner in successive serial passaging while maintaining insulin production in response to glucose. These cells are advantageous in that they are both expandable and stable in culture and can driven to late stage development, i.e. prototype islet cells. This invention further provides for culturing techniques that select for these intermediate differentiated stage cells and selectively eliminates early or late stage pancreatic cells.
    Type: Application
    Filed: February 10, 2004
    Publication date: July 22, 2004
    Applicant: AmCyte, Inc.
    Inventors: Wen-Ghih Tsang, Tianli Zheng, Chang Jiang Huang
  • Patent number: 6759039
    Abstract: This invention relates to the discovery that an intermediate, differentiated stage of pancreatic stem cells exist that can be propagated in a stable manner in successive serial passaging while maintaining insulin production in response to glucose. These cells are advantageous in that they are both expandable and stable in culture and can driven to late stage development, i.e. prototype islet cells. This invention further provides for culturing techniques that select for these intermediate differentiated stage cells and selectively eliminates early or late stage pancreatic cells.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: July 6, 2004
    Assignee: AmCyte, Inc.
    Inventors: Wen-Ghih Tsang, Tianli Zheng, Chang Jiang Huang
  • Publication number: 20040115805
    Abstract: The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stems cells having a high propensity to differentiate into insulin producing cells or into insulin producing cell aggregates.
    Type: Application
    Filed: September 8, 2003
    Publication date: June 17, 2004
    Applicant: AmCyte Inc.
    Inventors: Wen-Ghih Tsang, Tianli Zheng, Wei Liu
  • Publication number: 20030170215
    Abstract: This invention relates to the discovery that an intermediate, differentiated stage of pancreatic stem cells exist that can be matured in situ into a stable cell line that produces insulin in response to glucose. These cells are advantageous in that they are both expandable and stable in culture. This invention avoids the step of culturing the intermediate stage stem cells into later stage pancreatic cells.
    Type: Application
    Filed: December 20, 2002
    Publication date: September 11, 2003
    Applicant: AmCyte, Inc.
    Inventors: Wen-Ghih Tsang, Tianli Zheng, Yanping Wang
  • Publication number: 20020081725
    Abstract: This invention relates to the discovery that an intermediate, differentiated stage of pancreatic stem cells exist that can be propagated in a stable manner in successive serial passaging while maintaining insulin production in response to glucose. These cells are advantageous in that they are both expandable and stable in culture and can driven to late stage development, i.e. prototype islet cells. This invention further provides for culturing techniques that select for these intermediate differentiated stage cells and selectively eliminates early or late stage pancreatic cells.
    Type: Application
    Filed: June 29, 2001
    Publication date: June 27, 2002
    Inventors: Wen-Ghih Tsang, Tianli Zheng, Chang Jiang Huang
  • Patent number: 5916596
    Abstract: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered.
    Type: Grant
    Filed: October 1, 1996
    Date of Patent: June 29, 1999
    Assignee: Vivorx Pharmaceuticals, Inc.
    Inventors: Neil P. Desai, Chunlin Tao, Andrew Yang, Leslie Louie, Tianli Zheng, Zhiwen Yao, Patrick Soon-Shiong, Shlomo Magdassi